our Premium Content: News alerts, weekly reports and conference planners

GENE:

YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

News alerts, weekly reports and conference planners

10d

CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA. (PubMed, Exp Mol Med)

Notably, targeting CDK13 with the small-molecule inhibitor 1NM-PP1 potentiates METTL16 depletion-mediated anticancer effects. Our findings establish a kinase-RNA modifier axis that links CDK13 to epitranscriptomic control of lipid metabolism, positioning the CDK13-METTL16-ACLY pathway as a promising target for precision therapies against ccRCC.

10 days ago

Journal

CDK13 (Cyclin Dependent Kinase 13) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • METTL16 (Methyltransferase 16, RNA N6-Adenosine)

21d

m6A methylation dependent autophagy activation is required for anti-tumor effects of artesunate through ferroptosis in hepatocellular carcinoma. (PubMed, Chem Biol Interact)

Art emerges as a clinically potential HCC therapeutic that elicits its oncosuppressive activity through WTAP/YTHDC2-mediated m6A methylation of ATG5 transcripts, thereby causes ferroptosis of HCC mediated by autophagy.

21 days ago

Journal

ATG5 (Autophagy Related 5) • WTAP (WT1 Associated Protein) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

21d

N6-methyladenosine RNA methylation regulators and their target SOX2 as circulating biomarkers of colorectal cancer: Insights towards early diagnosis and staging. (PubMed, Comput Biol Med)

We developed a novel predictive panel of serum m6A-related genes that could empower CRC screening and early diagnosis. METTL14, ALKBH5, YTHDC2 expression, and SOX2 protein correlate with tumor-related data and are candidates for CRC prognosis.

21 days ago

Journal

SOX2 • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)

23d

Fuzheng Shengbai Decoction Enhances Antitumor Immunity via YTHDC2-Dependent Stabilization of CLCA2 mRNA in Colorectal Cancer. (PubMed, J Ethnopharmacol)

FZSB enhances anti-colorectal cancer immune responses and is associated with increased CD8+ T-cell activation, while concurrently modulating the YTHDC2-CLCA2 axis via m6A -mediated mRNA stabilization.

23 days ago

Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

2ms

METTL3-mediated m6A modification of TACSTD2 mRNA inhibits papillary thyroid cancer progression by activating the TNF signaling and blocking epithelial-mesenchymal transition. (PubMed, Sci Rep)

Collectively, METTL3-modulated m6A modification of TACSTD2 exerts an indispensable tumor-suppressive function in PTC progression. The METTL3/TACSTD2/YTHDC2 axis may serve as a molecular target for PTC therapy.

2 months ago

Journal

METTL3 (Methyltransferase Like 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

2ms

YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis. (PubMed, Oncogene)

Additionally, we found that the copper ionophore disulfiram (DSF) overcame osimertinib resistance by augmenting YTHDC2 expression. Collectively, our findings elucidate a novel YTHDC2-SLC31A1-cuproptosis axis as a key mechanism underlying EGFR-TKI resistance and propose new therapeutic strategies for its reversal.

2 months ago

Journal

SLC31A1 (Solute Carrier Family 31 Member 1) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

Tagrisso (osimertinib)

2ms

Dynamics and regulatory role of 5-methylcytosine modification in mRNA colocalized with RNA G-quadruplex structure in mouse development. (PubMed, Mamm Genome)

Collectively, these analyses provide an insight into the interplay between the m5C modification and rG4 to fine-tune the post-transcriptional regulation during development. It also suggests the possible involvement of m5C colocalized sites with PQS in modulating the expression of oncogene Hdgf, as well as the oncogenic and therapeutic targets like Med24 and Emc3.

2 months ago

Preclinical • Journal

HDGF (Heparin Binding Growth Factor) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • YY1 (YY1 Transcription Factor)

2ms

Prognostic potential of N6-methyladenosine methylation-associated genes in lung adenocarcinoma. (PubMed, Transl Cancer Res)

Our study constructed a novel signature associated with m6A modifications, which can serve as a promising prognostic indicator for LUAD. These findings may provide valuable insights into diagnosis and therapeutic strategies for patients with LUAD.

2 months ago

Journal

FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • RBM15 (RNA Binding Motif Protein 15) • VIRMA (Vir Like M6A Methyltransferase Associated) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)

3ms

Cigarette smoke-mediated YTHDC2 suppression drives macrophage senescence and a tumor-promoting microenvironment in lung cancer. (PubMed, Immunol Cell Biol)

In vivo studies using a cigarette smoke-exposed lung cancer model confirmed the role of YTHDC2 in smoke-induced immune microenvironment modulation and tumor progression. These findings identify YTHDC2 as a critical regulator of smoke-induced macrophage senescence and the tumor-promoting microenvironment, providing a potential therapeutic target for lung cancer in smokers.

3 months ago

Journal

YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

4ms

YTHDC2 suppresses bladder cancer by inhibiting SOX2-mediated tumor plasticity. (PubMed, Cell Death Dis)

Mechanistically, YTHDC2 recognized and bound to m6A-modified SOX2 mRNA, resulting in translational inhibition of SOX2. In conclusion, our study identifies YTHDC2 as a tumor suppressor in bladder cancer through inhibiting SOX2-mediated cell pluripotency and underscores the therapeutic potential of targeting the YTHDC2-SOX2 axis in bladder cancer.

4 months ago

Journal

SOX2 • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

5ms

Proteomic analysis of human topoisomerases reveals their distinct and diverse cellular functions. (PubMed, Mol Cell Proteomics)

We further examined dynamic changes in these interactomes in response to TOP1 and TOP2 poisons and replication stress, distinguishing between interactions in chromatin and soluble fractions. These findings provide new insights into the regulation and functional coordination of human topoisomerases, offering potential biomarkers or therapeutic targets for topoisomerase inhibitors in cancer treatment.

5 months ago

Journal

YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)

5ms

Integration of eQTL and GEO Datasets to Identify Genes Associated with Breast Ductal Carcinoma In Situ. (PubMed, Curr Issues Mol Biol)

Thirteen genes were associated with DCIS progression, and six genes were validated in the cell experiments. KEGG and GO analyses highlight TME's role in early breast cancer, enhancing understanding of DCIS occurrence and aiding identification of high-risk tumors.

5 months ago

Journal

PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • CYB5R2 (Cytochrome B5 Reductase 2) • GPX3 (Glutathione Peroxidase 3) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)